Page 51 - 2019_06-Haematologica-web

The role of rituximab in ITP
18. Beer JH, Rabaglio M, Berchtold P, et al. Autoantibodies against the platelet glyco- proteins (GP) IIb/IIIa, Ia/IIa, and IV and par- tial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction. Blood. 1993;82(3):820- 828.
19. Kuwana M, Okazaki Y, Kaburaki J, et al. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002;168(7):3675-3682.
20. Kayser W, Mueller-Eckhardt C, Bhakdi S, et al. Platelet-associated complement C3 in thrombocytopenic states. Br J Haematol. 1983;54(3):353-363.
21. Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets cor- relates with a decrease in circulating imma- ture platelets in patients with immune thrombocytopenic purpura. Br J Haematol. 2010;148(4):638-645.
22. Zhu X, Zhang J, Wang Q, et al. Diminished expression of 2-GPI is associated with a reduced ability to mitigate complement acti- vation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. Ann Hematol. 2018;97 (4):641-654.
23. Unterberger U, Eichelberger B, Ulz A, Panzer S. Antibodies against complement- regulatory proteins on platelets in immune thrombocytopenia. Platelets. 2017;28(4): 409-413.
24. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoan- tibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-895.
25. Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med. 2015;21(1):47-54.
26. Jansen AJ, Peng J, Zhao HG, Hou M, Ni H. Sialidase inhibition to increase platelet counts: A new treatment option for throm- bocytopenia. Am J Hematol. 2015;90(5):E94-95.
27. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(19):4245-4254.
28. Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombo- cytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103(7):2645-2647.
29. Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idio- pathic thrombocytopenic purpura. Eur J Haematol. 2007;78(2):139-143.
30. Yu J, Heck S, Patel V, et al. Defective circulat- ing CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpu- ra. Blood. 2008;112(4):1325-1328.
31. Olsson B, Andersson PO, Jernas M, et al. T- cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic pur- pura. Nat Med. 2003;9(9):1123-1124.
32. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93(3):704-706.
33. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple trans- membrane domains. EMBO J. 1988;7(3): 711-717.
34. Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid
malignancies of B cell origin. J Clin Invest.
1981;67(1):134-140.
35. Weiner G. J. Rituximab: mechanism of
action. Semin Hematol. 2010;47(2):115-123. 36. Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood. 1998;92(9):
3490-3491.
37. Shvidel L, Klepfish A, Berrebi A. Successful
treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin’s lymphoma. Am J Hematol. 2001;67(3):213- 214.
38. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952-957.
39. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004.
40. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to ritux- imab therapy in children and adults with immune thrombocytopenia. Blood. 2012; 119(25):5989-5995.
41. Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228-3236.
42. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rit- uximab for adults with idiopathic thrombo- cytopenic purpura. Ann Intern Med. 2007;146(1):25-33.
43. Cervinek L, Cerna O, Caniga M, et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pre- treated patients from everyday hematologi- cal practice. Int J Hematol. 2012;96(5):594- 599.
44. Zaja F, Volpetti S, Chiozzotto M, et al. Long- term follow-up analysis after rituximab sal- vage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012;87 (9):886-889.
45. Mahévas M, Ebbo M, Audia S, et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard reg- imen to treat adult immune thrombocytope- nia. Am J Hematol. 2013;88(10):858-861.
46. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell deple- tion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocy- topenic purpura. Br J Haematol. 2004;125 (2):232-239.
47. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant ritux- imab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356-1362.
48. Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385 (9978):1653-1661.
49. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 mon- oclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lym- phoma. Blood. 1997;90(6):2188-2195.
50. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329-334.
51. Gracie C, Zaidi A, Doobaree U, et al.
Comparsion of standard and low-dose ritux- imab in primary immune thrombocytopenia (ITP): data from the UK ITP registry. EHA Abstr. 2018.
52. Tran H, Brighton T, Grigg A, et al. A multi- centre, single-arm, open-label study evaluat- ing the safety and efficacy of fixed dose rit- uximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol. 2014;167(2):243-251.
53. Zwaginga JJ, Van Der Holt B, Te Boekhorst PA, et al. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica. 2015;100(3):e90- 92.
54. Bussel JB, Lee CS, Seery C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99(7):1264-1271.
55. Chapin J, Lee CS, Zhang H, et al. Gender and duration of disease differentiate responses to rituximab–dexamethasone therapy in adults with immune thrombocy- topenia. Am J Hematol. (2016);91(9):907- 911.
56. Marangon M, Vianelli N, Palandri F, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98(4):371-377.
57. Peñalver FJ, Jimenez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85(6):400-406.
58. Zaja F, Vianelli N, Battista M, et al. Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol. 2006;34(5):571-572.
59. Provan D, Stasi R, Newland AC, et al. International consensus report on the inves- tigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2):168-186.
60. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evi- dence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16): 4190-4207.
61. Cooper N, Stasi R, Cunningham-Rundles S, et al. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol. 2012;158 (4):539-547.
62. Porcelijn L, Huiskes E, Schipperus M, et al. Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to ritux- imab treatment in ITP patients. Blood. 2017;129(25):3389-3391.
63. Arnold DM, Vrbensky JR, Karim N, et al. The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia. Br J Haematol. 2017;178(2):302-307.
64. Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12 (4):497-504.
65. Zeng Q, Zhu L, Tao L, et al. Relative efficacy of steroid therapy in immune thrombocy- topenia mediated by anti-platelet GPIIbIIIa versus GPIb antibodies. Am J Hematol. 2012;87(2):206-208.
haematologica | 2019; 104(6)
1133